Evidence map›Paper›PMID 26459182›Full record

ArticleCNS neuroscience & therapeutics2016

Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats.

Barbara Kosmowska, Jadwiga Wardas, Urszula Głowacka, Subramaniam Ananthan, Krystyna Ossowska

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03430596 (a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03430596 early_phase1completednot on this mapstarted 2018, after this paper: background citation

a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics

TypeinterventionalSponsorShanghai Mental Health CenterRan2018 to 2021Enrolled50ConditionsExtrapyramidal SyndromeArmsPramipexole, Trihexyphenidyl hydrochloride
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Barbara KosmowskaDepartment of Neuro-Psychopharmacology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
Jadwiga WardasDepartment of Neuro-Psychopharmacology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
Urszula GłowackaDepartment of Neuro-Psychopharmacology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
Subramaniam AnanthanDepartment of Chemistry, Southern Research Institute, Birmingham, AL, USA.
Krystyna OssowskaDepartment of Neuro-Psychopharmacology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.ORCID http://orcid.org/0000-0002-8381-6632
Maj Institute of Pharmacology · PLSouthern Research Institute · US

Funding

Development of Dopamine D3 Ligands as Medications for Psychostimulant AddictionR01DA024675 · NIDA · SOUTHERN RESEARCH INSTITUTE · PI ANANTHAN, SUBRAMANIAM · 2009 to 2011
$1.4M
NIDA NIH HHS R01 DA024675NIDA NIH HHS R01DA024675
6 · The paper itself

Abstract

aimsThe aim of the study was to examine the effects of preferential agonists of dopamine D3 receptors: pramipexole and 7-OH-DPAT on the harmaline-induced tremor in rats (a model of essential tremor, ET). To study receptor mechanisms of these drugs, rats were pretreated with dopamine D3 receptor antagonists--SB-277011-A and SR-21502, an antagonist of presynaptic D2/D3 receptors--amisulpride, or a nonselective antagonist of D2-like receptors, haloperidol, at a postsynaptic dose.

methodsFor tremor measurement, fully automated force plate actimeters were used and data were analyzed using fast Fourier transform.

resultsHarmaline (15 mg/kg ip)-triggered tremor was manifested by an increase in the power within 9-15 Hz band (AP2). Pramipexole administered at a low (0.1 mg/kg sc), but not higher doses (0.3 and 1 mg/kg sc), and 7-OH-DPAT (0.1, 0.3, and 1 mg/kg sc) reversed the harmaline-increased AP2. None of the examined dopamine antagonists: SB-277011-A (10 mg/kg ip), SR-21502 (15 mg/kg ip), haloperidol (0.5 mg/kg ip), or amisulpride (1 mg/kg ip) influenced the above effect of dopamine agonists.

conclusionThe present study indicates that pramipexole reduces the harmaline-induced tremor, which may suggest its beneficial effects in ET patients. However, mechanisms underlying its action are still unclear and need further examination.

Indexed as

AmisulprideAnimalsAnti-Dyskinesia AgentsBenzothiazolesDisease Models, AnimalDopamine AgonistsDopamine AntagonistsDose-Response Relationship, DrugEssential TremorHaloperidolHarmalineImidazolesMaleMovementNitrilesPramipexole7-hydroxy-2-N,N-dipropylaminotetralinAmisulprideAnti-Dyskinesia AgentsBenzothiazolesDopamine AgonistsDopamine AntagonistsDRD2 protein, ratDrd3 protein, ratHaloperidolHarmalineImidazolesNitrilesPramipexolePyridinesReceptors, Dopamine D2Receptors, Dopamine D3SB 277011SR 21502SulpirideTetrahydroisoquinolinesTetrahydronaphthalenesCerebellumDopamine receptorsEssential tremorHarmaline-induced tremorPramipexole

Identifiers

PMID26459182
PMCPMC6492867
OpenAlexW1960153579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.